Clinical Trial Update: Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of afatinib (BIBW 2992) and cetuximab in non-small cell lung cancer has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gilotrif (Afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2014-07-21